Basic Fibroblast Growth Factor
Also known as: Basic FGF, bFGF, FGF-2, FGF2, FGFB, Fiblast, Heparin-binding growth factor 2 (HBGF-2), Trafermin
Source Basic Fibroblast Growth Factor at Peptiology
Save 10% with code PEPTI-BOSSRABBIT-10
Tapping Shop Now & Save 10% copies your 10% off code PEPTI-BOSSRABBIT-10 to your clipboard. Paste it at the Peptiology checkout to claim the discount.
Summary
Basic fibroblast growth factor (FGF2) is a 18‑kDa heparin-binding protein that stimulates angiogenesis, wound healing, and embryonic development. It is widely used in cell culture and investigated for regenerative medicine.
Mechanism of Action
Binds fibroblast growth factor receptors (FGFR1-4) activating MAPK/ERK and PI3K/AKT pathways, promoting cell proliferation, angiogenesis, and tissue repair.
Routes of Administration
Goals & Uses
- Wound Healing / Pressure Ulcer TreatmentDermatology / Tissue RepairHigh
- Angiogenesis promotionVascularModerate
- Angiogenesis / NeovascularizationCardiovascularModerate
- Neuroprotection and Neural RepairNeurologyLow
- Wound healing accelerationRegenerative MedicineModerate
- Bone and Cartilage RegenerationOrthopedicsModerate
- Burns TreatmentDermatology / Wound CareHigh
- Stem Cell Maintenance and ExpansionCell Biology / ResearchHigh
Contraindications
- Active malignancyOncologyHighUse caution or avoid depending on agent and context
- Hypersensitivity to bFGF or Formulation ExcipientsAllergy / ImmunologyHigh
- PregnancyPopulationModeratePotential fetal risk or insufficient safety data
- Proliferative RetinopathyOphthalmologyModerate
Adverse Effects
- Fever / PyrexiaSystemicUncommon
- EdemaFluid BalanceUnknownSwelling from fluid retention
- ProteinuriaRenalUncommon
- Local Injection Site ReactionsDermatologicalCommon
- Antibody FormationImmunologicalUncommon
- HypotensionCardiovascularUncommonLow blood pressure
- Theoretical Oncogenic RiskOncologyUnknown
Drug Interactions
- HeparinModerate
- CorticosteroidsModerate
- VEGF Inhibitors (e.g., Bevacizumab)Low
Population Constraints
- Pediatric patientsAgeRelative
- Pregnant and Lactating WomenReproductiveRelative
- Diabetic PatientsMetabolicRelative
- Patients with History of MalignancyOncologyRelative
Regulatory Status
- European UnionInvestigationalClinical studies ongoing for chronic wounds.
- United StatesInvestigationalPhase I/II trials for peripheral artery disease.
- United KingdomInvestigationalResearch use only.
Not approved for therapeutic use; investigated in clinical trials for ischemic disease and wound repair.
Evidence & Sources
No sources recorded yet.
Frequently Asked Questions
What is Basic Fibroblast Growth Factor?
Basic fibroblast growth factor (FGF2) is a 18‑kDa heparin-binding protein that stimulates angiogenesis, wound healing, and embryonic development. It is widely used in cell culture and investigated for regenerative medicine.
What is Basic Fibroblast Growth Factor used for?
Basic Fibroblast Growth Factor is educationally associated with: Wound Healing / Pressure Ulcer Treatment, Angiogenesis promotion, Angiogenesis / Neovascularization, Neuroprotection and Neural Repair, Wound healing acceleration, Bone and Cartilage Regeneration, Burns Treatment, Stem Cell Maintenance and Expansion. Educational only — not medical advice.
How is Basic Fibroblast Growth Factor administered?
Recorded routes of administration: Intracoronary, Intramuscular, Intravenous, Subcutaneous, Topical.
What are the potential side effects of Basic Fibroblast Growth Factor?
Reported adverse effects include: Fever / Pyrexia, Edema, Proteinuria, Local Injection Site Reactions, Antibody Formation, Hypotension, Theoretical Oncogenic Risk. This list is not exhaustive — consult a qualified clinician.
Who should avoid Basic Fibroblast Growth Factor?
Recorded contraindications: Active malignancy, Hypersensitivity to bFGF or Formulation Excipients, Pregnancy, Proliferative Retinopathy. Consult a qualified clinician before use.